These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 11434937)

  • 1. Mechanism of action of bimatoprost (Lumigan).
    Brubaker RF
    Surv Ophthalmol; 2001 May; 45 Suppl 4():S347-51. PubMed ID: 11434937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of ocular hypotensive action of bimatoprost (Lumigan) in patients with ocular hypertension or glaucoma.
    Christiansen GA; Nau CB; McLaren JW; Johnson DH
    Ophthalmology; 2004 Sep; 111(9):1658-62. PubMed ID: 15350319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study.
    Lim KS; Nau CB; O'Byrne MM; Hodge DO; Toris CB; McLaren JW; Johnson DH
    Ophthalmology; 2008 May; 115(5):790-795.e4. PubMed ID: 18452763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics.
    Brubaker RF; Schoff EO; Nau CB; Carpenter SP; Chen K; Vandenburgh AM
    Am J Ophthalmol; 2001 Jan; 131(1):19-24. PubMed ID: 11162974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aqueous humor concentrations of bimatoprost free acid, bimatoprost and travoprost free acid in cataract surgical patients administered multiple topical ocular doses of LUMIGAN or TRAVATAN.
    Faulkner R; Sharif NA; Orr S; Sall K; Dubiner H; Whitson JT; Moster M; Craven ER; Curtis M; Pailliotet C; Martens K; Dahlin D
    J Ocul Pharmacol Ther; 2010 Apr; 26(2):147-56. PubMed ID: 20307216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacology of bimatoprost.
    Cantor LB
    Expert Opin Drug Metab Toxicol; 2005 Jun; 1(1):151-7. PubMed ID: 16922657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension.
    Easthope SE; Perry CM
    Drugs Aging; 2002; 19(3):231-48. PubMed ID: 12027782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of prostaglandin analogues on IOP in prostanoid FP-receptor-deficient mice.
    Ota T; Aihara M; Narumiya S; Araie M
    Invest Ophthalmol Vis Sci; 2005 Nov; 46(11):4159-63. PubMed ID: 16249494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacology of bimatoprost (Lumigan).
    Woodward DF; Krauss AH; Chen J; Lai RK; Spada CS; Burk RM; Andrews SW; Shi L; Liang Y; Kedzie KM; Chen R; Gil DW; Kharlamb A; Archeampong A; Ling J; Madhu C; Ni J; Rix P; Usansky J; Usansky H; Weber A; Welty D; Yang W; Tang-Liu DD; Garst ME; Brar B; Wheeler LA; Kaplan LJ
    Surv Ophthalmol; 2001 May; 45 Suppl 4():S337-45. PubMed ID: 11434936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of bimatoprost on intraocular pressure in prostaglandin FP receptor knockout mice.
    Crowston JG; Lindsey JD; Morris CA; Wheeler L; Medeiros FA; Weinreb RN
    Invest Ophthalmol Vis Sci; 2005 Dec; 46(12):4571-7. PubMed ID: 16303950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting outflow facility in glaucoma management.
    Brubaker RF
    Surv Ophthalmol; 2003 Apr; 48 Suppl 1():S17-20. PubMed ID: 12852430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cellular basis for bimatoprost effects on human conventional outflow.
    Stamer WD; Piwnica D; Jolas T; Carling RW; Cornell CL; Fliri H; Martos J; Pettit SN; Wang JW; Woodward DF
    Invest Ophthalmol Vis Sci; 2010 Oct; 51(10):5176-81. PubMed ID: 20435598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intraocular Pressure-Lowering Activity of NCX 470, a Novel Nitric Oxide-Donating Bimatoprost in Preclinical Models.
    Impagnatiello F; Toris CB; Batugo M; Prasanna G; Borghi V; Bastia E; Ongini E; Krauss AH
    Invest Ophthalmol Vis Sci; 2015 Oct; 56(11):6558-64. PubMed ID: 26457541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 3-month randomized controlled trial of bimatoprost (LUMIGAN) versus combined timolol and dorzolamide (Cosopt) in patients with glaucoma or ocular hypertension.
    Coleman AL; Lerner F; Bernstein P; Whitcup SM
    Ophthalmology; 2003 Dec; 110(12):2362-8. PubMed ID: 14644719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A dual acting compound with latanoprost amide and nitric oxide releasing properties, shows ocular hypotensive effects in rabbits and dogs.
    Impagnatiello F; Borghi V; Gale DC; Batugo M; Guzzetta M; Brambilla S; Carreiro ST; Chong WK; Prasanna G; Chiroli V; Ongini E; Krauss AH
    Exp Eye Res; 2011 Sep; 93(3):243-9. PubMed ID: 21356209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of travoprost on aqueous humor dynamics in monkeys.
    Toris CB; Zhan GL; Camras CB; McLaughlin MA
    J Glaucoma; 2005 Feb; 14(1):70-3. PubMed ID: 15650608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Additivity of bimatoprost or travoprost to latanoprost in glaucomatous monkey eyes.
    Gagliuso DJ; Wang RF; Mittag TW; Podos SM
    Arch Ophthalmol; 2004 Sep; 122(9):1342-7. PubMed ID: 15364714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of monotherapy treatment of glaucoma and ocular hypertension with the lipid class of medications.
    Noecker RJ; Walt JG
    Am J Ophthalmol; 2006 Jan; 141(1 Suppl):S15-21. PubMed ID: 16389056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of bimatoprost on ocular circulation in patients with open-angle glaucoma or ocular hypertension.
    Akarsu C; Yilmaz S; Taner P; Ergin A
    Graefes Arch Clin Exp Ophthalmol; 2004 Oct; 242(10):814-8. PubMed ID: 15069567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bimatoprost.
    Medeiros FA; Susanna R
    Ophthalmology; 2005 Aug; 112(8):1478; author reply 1479. PubMed ID: 16061098
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.